News headlines about Agile Therapeutics (NASDAQ:AGRX) have trended somewhat positive recently, according to Accern. The research group identifies negative and positive media coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Agile Therapeutics earned a media sentiment score of 0.23 on Accern’s scale. Accern also assigned news stories about the specialty pharmaceutical company an impact score of 48.5370935788406 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
These are some of the news stories that may have effected Accern’s rankings:
- Abstract on AG200-15 (Twirla®) Accepted for Presentation at the APhA 2018 Annual Meeting & Exposition – GlobeNewswire (press release) (globenewswire.com)
- -$0.28 EPS Expected for Agile Therapeutics Inc (AGRX) This Quarter (americanbankingnews.com)
- HC Wainwright Reaffirms “Buy” Rating for Agile Therapeutics (AGRX) (americanbankingnews.com)
- Agile Therapeutics Reports Fourth Quarter and Full Year 2017 … – Nasdaq (nasdaq.com)
AGRX has been the subject of a number of research analyst reports. Cantor Fitzgerald reissued a “buy” rating and set a $8.00 target price on shares of Agile Therapeutics in a report on Monday, November 20th. HC Wainwright set a $8.00 target price on Agile Therapeutics and gave the company a “buy” rating in a report on Friday, December 22nd. Janney Montgomery Scott cut Agile Therapeutics from a “buy” rating to a “neutral” rating in a report on Friday, December 22nd. Noble Financial reissued a “buy” rating on shares of Agile Therapeutics in a report on Friday, December 22nd. Finally, William Blair cut Agile Therapeutics from an “outperform” rating to a “market perform” rating in a report on Tuesday, December 26th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and an average target price of $9.00.
TRADEMARK VIOLATION WARNING: “Agile Therapeutics (AGRX) Receives Media Impact Rating of 0.23” was first published by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this article on another site, it was copied illegally and republished in violation of U.S. and international trademark and copyright law. The correct version of this article can be viewed at https://sportsperspectives.com/2018/03/14/agile-therapeutics-agrx-receives-media-impact-rating-of-0-23.html.
Agile Therapeutics Company Profile
Agile Therapeutics, Inc is a women’s health specialty pharmaceutical company. The Company is focused in the development and commercialization of prescription contraceptive products. The Company has developed a transdermal patch technology, called Skinfusion. The Company’s lead product candidate is Twirla, also known as AG200-15, is a combined hormonal contraceptive (CHC) patch.
Receive News & Ratings for Agile Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.